Prescribing of psychotropic medications increases significantly following a Parkinson's disease diagnosis, highlighting the need for proactive monitoring of off-label psychiatric drug use in this population.
Tortugas Neuroscience has launched with $106M in funding to advance mid-stage clinical trials for schizophrenia, tinnitus, focal epilepsy, and encephalopathy drugs licensed from Chinese and Japanese pharmaceutical partners.
Compass Pathways stock surged following reports of former President Trump's support for psilocybin-based therapies, signaling potential regulatory momentum for psychedelic drug development.
This case report highlights that osmotic demyelination syndrome (ODS) can mimic extrapyramidal symptoms and cause neuroleptic sensitivity, necessitating the evaluation of electrolyte status in patients presenting with atypical movement disorders.
This podcast discusses the emerging potential of GLP-1 agonists to treat psychiatric conditions and mitigate metabolic side effects of antipsychotics like clozapine, challenging traditional monoamine-based treatment paradigms.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Oct 08 – Apr 21)
- In Alzheimer's patients with type 2 diabetes, prefer aripiprazole or quetiapine over olanzapine or risperidone to reduce all-cause mortality and cardiovascular risks.
- Monitor dementia patients closely for cerebrovascular events after the first four weeks of risperidone treatment, as adverse effects often emerge during this period.
- Consider vortioxetine as a multimodal serotonergic option for major depressive disorder when evidence-based efficacy and a favorable side effect profile are prioritized.
- Adopt a risk-based rather than universal ECG monitoring strategy for pediatric patients on antipsychotics, given that clinically significant QTc prolongation is rare despite common abnormalities.
- Investigate alternative causes for symptom worsening in ADHD patients before assuming drug tolerance, as evidence suggests long-term therapeutic tolerance is minimal.
- Monitor serum potassium levels in patients with preexisting cardiac conditions who are prescribed valproic acid to prevent dose-dependent hyperkalemia and conduction abnormalities.
- Prioritize right unilateral electroconvulsive therapy over algorithm-based pharmacotherapy for acute symptom improvement in treatment-resistant bipolar depression, noting comparable long-term outcomes.
- Evaluate the potential of leucovorin (folinic acid) for autism features in patients with folate receptor alpha autoantibodies following recent FDA label updates.
- Be aware that antipsychotics impair pancreatic beta-cell insulin secretion via dopaminergic mechanisms, necessitating proactive management of glucose dysregulation.
- Recognize that intravenous ketamine is now an approved option for severe suicidal crises in France, signaling a shift toward rapid-acting parenteral interventions for acute safety.
Diagnosis & Treatment 3
This article series frames antipsychotic deprescribing in schizophrenia as a complex care system issue requiring structured support rather than attributing discontinuation solely to patient non-compliance.
This case highlights the critical risk of misdiagnosing Guillain-Barré syndrome as catatonia in patients with schizophrenia, emphasizing the need for thorough neurological examination and CSF analysis to distinguish medical causes from psychiatric symptoms.
This article argues for prioritizing empiric treatment with lorazepam or ECT in suspected catatonia cases to mitigate high mortality risks, addressing barriers like underdiagnosis and clinician hesitation regarding benzodiazepine dosing.
Drug Development 3
This completed trial investigates the adjunctive use of the dietary supplement Ashwagandha alongside risperidone to improve BDNF levels and cognitive function in patients with schizophrenia.
A case study of identical twins indicates that repeated low-dose psilocybin reduces OCD symptom severity but fails to restore cognitive flexibility deficits.
Podcast Summary 3
This podcast discusses the HAMLETT study's finding that psychiatrist-specific factors significantly influence antipsychotic outcomes in first-episode psychosis, alongside key evidence on early tapering strategies and dopamine supersensitivity.
This podcast provides an evidence-based overview of Dissociative Identity Disorder (DID) etiology and treatment but does not report new pharmacological data or prescribing guidelines.
This podcast details the assessment of violence-associated delusions in forensic settings and highlights clozapine as a key pharmacological intervention for reducing violence risk alongside cognitive behavioral therapy.
Policy & Regulation 5
A Trump executive order aims to accelerate research and access to psychedelics for mental health conditions, potentially influencing the investment landscape for related biotechs.
President Trump signed an executive order to boost federal research into psychedelics like psilocybin, LSD, and MDMA for potential mental health treatments.
Virginia establishes regulatory frameworks for potential psilocybin-assisted therapy, signaling a shift in state-level policy regarding this emerging psychopharmacological treatment.
President Trump's endorsement to expedite psychedelic development signals potential regulatory acceleration for psychotropic agents targeting severe mental health conditions.
A presidential executive order directs the FDA to expedite reviews and establish a regulatory pathway for psychedelic compounds in mental health treatment, signaling administrative support despite concerns regarding the politicization of research.
Digital Health 5
A clinical trial is recruiting to evaluate transcranial photobiomodulation as an intervention for somatic symptoms in treatment-resistant depression.
A randomized controlled trial demonstrates that internet-delivered psychodynamic therapy and cognitive-behavioral therapy yield comparable 12-month outcomes and costs for adolescent depression, offering viable non-pharmacologic treatment alternatives.
A multicenter cohort study demonstrates that implementing smart digital screening tools for high-risk psychiatric patients significantly reduces emergency department visits by prioritizing rapid outpatient evaluation.
This article describes a clinical trial evaluating internet-based cognitive behavioral therapy for mild-to-moderate anxiety and depression in Singapore.
This article describes a clinical trial evaluating whether early brainwave biomarkers can optimize personalized transcranial magnetic stimulation protocols for treatment-resistant depression.
Neuroscience 4
This systematic review identifies pretreatment subcallosal cingulate functional connectivity patterns as potential biomarkers for predicting response to brain stimulation therapies (DBS, rTMS, ECT, TUS) in treatment-resistant depression.
This review details how cerebral iron dyshomeostasis contributes to the pathophysiology of neuropsychiatric disorders like depression, schizophrenia, and ADHD, identifying iron metabolism as a potential therapeutic target.
This study elucidates the molecular mechanism by which SHANK3-mediated phase separation regulates postsynaptic density remodeling and AMPA receptor trafficking during long-term potentiation, with specific relevance to autism spectrum disorders.
This study demonstrates that stress levels correlate with reduced synaptic density in healthy controls but not in individuals with first-episode psychosis or clinical high risk, suggesting impaired adaptive neuroplasticity as a mechanism for psychosis vulnerability.
Mechanism of Action 5
A study identifying a specific serotonin circuit linking SSRIs to tinnitus provides a mechanistic explanation for this adverse effect and suggests a potential therapeutic target.
This systematic review elucidates the mechanism by which dopaminergic modulation of pancreatic beta-cells contributes to antipsychotic-induced glucose dysregulation, offering critical mechanistic insight for managing metabolic side effects in patients treated with antipsychotics.
This systematic review elucidates the dopaminergic mechanisms by which antipsychotics impair pancreatic beta-cell insulin secretion, providing mechanistic evidence to explain and manage antipsychotic-induced glucose dysregulation.
A systematic review indicates that probiotic interventions may induce neurobiological changes associated with improved psychiatric symptoms, though further research is needed to confirm efficacy and clarify mechanisms.
This article identifies mTOR-driven autophagy-inflammation crosstalk as a core mechanism in schizophrenia pathophysiology, suggesting potential targets for future pharmacological intervention.
Clinical Pearl 5
This cohort study of 430 pediatric patients on antipsychotics found that while ECG abnormalities were common (45.5%), clinically significant QTc prolongation was rare (5.6%) and transient, supporting a risk-based rather than universal monitoring strategy.
This Phase 3 clinical trial investigates whether perioperative dexmedetomidine reduces post-procedure grief and PTSD symptoms following second-trimester abortion, representing a potential new pharmacological application for an existing sedative.
This clinical trial investigates functional changes in the frontotemporal cortex during ECT and MST for MDD using fNIRS, a methodology relevant to understanding treatment mechanisms but currently not yet recruiting.
This article describes a clinical trial comparing venous and arterial tourniquets for seizure monitoring during electroconvulsive therapy (ECT), a procedure used to treat major depressive disorder, bipolar disorder, and schizophrenia.
This is a clinical trial comparing venous versus arterial tourniquets for seizure monitoring during ECT, a critical safety parameter in electroconvulsive therapy.
Clinical Trials 1
A clinical trial is recruiting to evaluate the effects of Dextromethorphan-Bupropion on striatal activity in adults with Major Depressive Disorder.
Substance Use 1
A common antidepressant demonstrates efficacy in reducing methamphetamine use, offering a potential pharmacological treatment option for substance use disorder.
Journal Article 1
This large-scale meta-analysis evaluates the efficacy and clinical interpretability of interventions for negative symptoms in schizophrenia, providing critical evidence to guide antipsychotic selection and adjunctive treatment strategies.
Uncategorized 5
Biovac nets $108M finance package to build Africa’s first fully integrated vaccine plant
Bayer falls short in bid to block J&J’s survival claims in prostate cancer clash